Toralgen

Landmark Research on Oral Delivery System that Could Transform Diabetes Care Published in Nature Bio

Toralgen and Yale scientists demonstrate an oral drug delivery platform that will enable improved compliance and patient experience for biotherapeutics such as those used to treat diabetes.

Toralgen adds Ed Bastyr as Chief Medical Officer

INDIANAPOLIS, Indiana (April 28, 2021) – Toralgen, an Indiana-based biotechnology company focused on improving the delivery of biologics today announced the addition of Ed Bastyr III, MD to the newly created role of chief medical officer/clinical adviser.

GlobalData Healthcare coverage of Toralgen

GlobalData Healthcare highlights Toralgen's drug deliver platform potential in diabetes: "Toralgen’s technology provides a significant promise to oral delivery of major diabetic therapies"

StartUs Insights names Toralgen to Top 5 Drug Delivery Startup list

StartUs evaluated 266 emerging Biotech start-ups and highlighted Toralgen as one of 5 promising drug delivery startups.

Toralgen Closes $8.3 Million Seed Funding Roun

INDIANAPOLIS, IN., December 14, 2020 – Toralgen, an Indiana-based biotechnology company has announced the successful completion of its second seed funding round, raising a total of $8.3 million.

FiercePharma article: FDA let’s Toralgen’s insulin delivery nanopill into tech scheme

FIND OUT MORE